Literature DB >> 15015639

Immunohistochemical studies of the expression of matrix metalloproteinase-2 and metalloproteinase-9 in human prostate cancer.

Hanqing Zeng1, Yajun Xiao, Gongchen Lu, Yong Chen.   

Abstract

To study the expression of matrix metalloproteinase-2 and -9 in human prostate cancer, matrix metalloproteinase-2 and -9 were immunohistochemically detected in tissues of prostate cancer and benign prostatic hyperplasia (BPH). Our results showed that matrix metalloproteinase-2 and -9 levels in prostate cancer were much higher than those in tissues of BPH, with the cancer invasion being positively correlated with the expression of the metalloproteinases. It is concluded that matrix metalloproteinase-2 and -9 are better molecular markers, which are of help in the diagnosis and prediction of prognosis of prostate cancer.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 15015639     DOI： 10.1007/BF02829421

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN： 1672-0733


  7 in total

1.  In situ hybridization studies of metalloproteinases 2 and 9 and TIMP-1 and TIMP-2 expression in human prostate cancer.

Authors:  M Wood; K Fudge; J L Mohler; A R Frost; F Garcia; M Wang; M E Stearns
Journal:  Clin Exp Metastasis       Date:  1997-05       Impact factor: 5.150

2.  Activation of the precursor of gelatinase A/72 kDa type IV collagenase/MMP-2 in lung carcinomas correlates with the expression of membrane-type matrix metalloproteinase (MT-MMP) and with lymph node metastasis.

Authors:  M Tokuraku; H Sato; S Murakami; Y Okada; Y Watanabe; M Seiki
Journal:  Int J Cancer       Date:  1995-10-20       Impact factor: 7.396

3.  Evidence for increased activated metalloproteinase 2 (MMP-2a) expression associated with human prostate cancer progression.

Authors:  M Stearns; M E Stearns
Journal:  Oncol Res       Date:  1996       Impact factor: 5.574

4.  M(r) 92,000 type IV collagenase is increased in plasma of patients with colon cancer and breast cancer.

Authors:  S Zucker; R M Lysik; M H Zarrabi; U Moll
Journal:  Cancer Res       Date:  1993-01-01       Impact factor: 12.701

5.  Expression of the metalloproteinase matrilysin in DU-145 cells increases their invasive potential in severe combined immunodeficient mice.

Authors:  W C Powell; J D Knox; M Navre; T M Grogan; J Kittelson; R B Nagle; G T Bowden
Journal:  Cancer Res       Date:  1993-01-15       Impact factor: 12.701

6.  Expression of the cellular adhesion molecule E-cadherin is reduced or absent in high-grade prostate cancer.

Authors:  R Umbas; J A Schalken; T W Aalders; B S Carter; H F Karthaus; H E Schaafsma; F M Debruyne; W B Isaacs
Journal:  Cancer Res       Date:  1992-09-15       Impact factor: 12.701

7.  Metastatic NIH 3T3 x LTA cell hybrids express 72 kDa type IV collagenase.

Authors:  J W Xuan; S M Wilson; J L Chin; A F Chambers
Journal:  Anticancer Res       Date:  1995 Jul-Aug       Impact factor: 2.480
  7 in total
  2 in total

1.  Small integrin-binding proteins as serum markers for prostate cancer detection.

Authors:  Alka Jain; Dianalee A McKnight; Larry W Fisher; Elizabeth B Humphreys; Leslie A Mangold; Alan W Partin; Neal S Fedarko
Journal:  Clin Cancer Res       Date:  2009-08-11       Impact factor: 12.531

Review 2.  The Role of the Metzincin Superfamily in Prostate Cancer Progression: A Systematic-Like Review.

Authors:  Marley J Binder; Alister C Ward
Journal:  Int J Mol Sci       Date:  2021-03-30       Impact factor: 5.923
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.